Show simple item record

dc.contributor.authorKeraite, I
dc.contributor.authorAlvarez-Garcia, V
dc.contributor.authorGarcia-Murillas, I
dc.contributor.authorBeaney, M
dc.contributor.authorTurner, NC
dc.contributor.authorBartos, C
dc.contributor.authorOikonomidou, O
dc.contributor.authorKersaudy-Kerhoas, M
dc.contributor.authorLeslie, NR
dc.date.accessioned2020-12-01T17:09:35Z
dc.date.issued2020-10-13
dc.identifier.citationScientific reports, 2020, 10 (1), pp. 17082 - ?
dc.identifier.issn2045-2322
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4250
dc.identifier.eissn2045-2322
dc.identifier.doi10.1038/s41598-020-74086-w
dc.description.abstractPIK3CA is one of the two most frequently mutated genes in breast cancers, occurring in 30-40% of cases. Four frequent 'hotspot' PIK3CA mutations (E542K, E545K, H1047R and H1047L) account for 80-90% of all PIK3CA mutations in human malignancies and represent predictive biomarkers. Here we describe a PIK3CA mutation specific nuclease-based enrichment assay, which combined with a low-cost real-time qPCR detection method, enhances assay detection sensitivity from 5% for E542K and 10% for E545K to 0.6%, and from 5% for H1047R to 0.3%. Moreover, we present a novel flexible prediction method to calculate initial mutant allele frequency in tissue biopsy and blood samples with low mutant fraction. These advancements demonstrated a quick, accurate and simple detection and quantitation of PIK3CA mutations in two breast cancer cohorts (first cohort n = 22, second cohort n = 25). Hence this simple, versatile and informative workflow could be applicable for routine diagnostic testing where quantitative results are essential, e.g. disease monitoring subject to validation in a substantial future study.
dc.formatElectronic
dc.format.extent17082 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PORTFOLIO
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePIK3CA mutation enrichment and quantitation from blood and tissue.
dc.typeJournal Article
dcterms.dateAccepted2020-09-14
rioxxterms.versionofrecord10.1038/s41598-020-74086-w
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-10-13
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfScientific reports
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamMolecular Oncology
dc.contributor.icrauthorGarcia-Murillas, Isaac
dc.contributor.icrauthorTurner, Nicholas


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0